158 related articles for article (PubMed ID: 10994663)
1. Association of prostate-specific antigen levels and patterns of benign and malignant uptake detected. on bone scintigraphy in patients with newly diagnosed prostate carcinoma.
Jacobson AF
Nucl Med Commun; 2000 Jul; 21(7):617-22. PubMed ID: 10994663
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. [Comparison of serum prostate specific antigen levels and bone scintigraphy in patients with prostate carcinoma].
Bielickaite J; Zadeikaite R; Jurkiene N; Kiudelis J; Kuprionis G
Medicina (Kaunas); 2003; 39(9):867-71. PubMed ID: 14515049
[TBL] [Abstract][Full Text] [Related]
4. Is bone scintigraphy necessary in initial staging of prostate cancer patients?
Jaukovic L; Adjinovic B; Cerovic S; Joksimovic M; Soldatovic Z
Hell J Nucl Med; 2011; 14(2):126-30. PubMed ID: 21761013
[TBL] [Abstract][Full Text] [Related]
5. When is a bone scan study appropriate in asymptomatic men diagnosed with prostate cancer?
Pal RP; Thiruudaian T; Khan MA
Asian J Androl; 2008 Nov; 10(6):890-5. PubMed ID: 18958353
[TBL] [Abstract][Full Text] [Related]
6. Influence of local tumour stage and grade on reliability of serum prostate-specific antigen in predicting skeletal metastases in patients with adenocarcinoma of the prostate.
Bruwer G; Heyns CF; Allen FJ
Eur Urol; 1999; 35(3):223-7. PubMed ID: 10072624
[TBL] [Abstract][Full Text] [Related]
7. The value of a baseline bone scan in patients with newly diagnosed prostate cancer.
Lin K; Szabo Z; Chin BB; Civelek AC
Clin Nucl Med; 1999 Aug; 24(8):579-82. PubMed ID: 10439178
[TBL] [Abstract][Full Text] [Related]
8. The CT flare response of metastatic bone disease in prostate cancer.
Messiou C; Cook G; Reid AH; Attard G; Dearnaley D; de Bono JS; de Souza NM
Acta Radiol; 2011 Jun; 52(5):557-61. PubMed ID: 21498309
[TBL] [Abstract][Full Text] [Related]
9. Multitargeted tyrosine kinase inhibition produces discordant changes between 99mTc-MDP bone scans and other disease biomarkers: analysis of a phase II study of sunitinib for metastatic castration-resistant prostate cancer.
Saylor PJ; Mahmood U; Kunawudhi A; Smith MR; Palmer EL; Michaelson MD
J Nucl Med; 2012 Nov; 53(11):1670-5. PubMed ID: 22984218
[TBL] [Abstract][Full Text] [Related]
10. Serum osteocalcin measurements in prostate carcinoma patients with skeletal deposits shown by bone scintigram: comparison with serum PSA/PAP measurements.
Shih WJ; Wierzbinski B; Collins J; Magoun S; Chen IW; Ryo UY
J Nucl Med; 1990 Sep; 31(9):1486-9. PubMed ID: 1697617
[TBL] [Abstract][Full Text] [Related]
11. Are serial bone scans useful for the follow-up of clinically localized, low to intermediate grade prostate cancer managed with watchful observation alone?
Yap BK; Choo R; Deboer G; Klotz L; Danjoux C; Morton G
BJU Int; 2003 May; 91(7):613-7. PubMed ID: 12699470
[TBL] [Abstract][Full Text] [Related]
12. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters.
Chybowski FM; Keller JJ; Bergstralh EJ; Oesterling JE
J Urol; 1991 Feb; 145(2):313-8. PubMed ID: 1703240
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of PSA, free PSA, PSMA, and total and bone alkaline phosphatase levels compared to bone scans in the management of patients with metastatic prostate cancer.
Murphy GP; Troychak MJ; Cobb OE; Bowes VA; Kenny RJ; Barren RJ; Kenny GM; Ragde H; Holmes EH; Wolfert RL
Prostate; 1997 Oct; 33(2):141-6. PubMed ID: 9316655
[TBL] [Abstract][Full Text] [Related]
14. When to perform bone scintigraphy in patients with newly diagnosed prostate cancer? a retrospective study.
Lin Y; Mao Q; Chen B; Wang L; Liu B; Zheng X; Xie L
BMC Urol; 2017 Jun; 17(1):41. PubMed ID: 28606069
[TBL] [Abstract][Full Text] [Related]
15. The relationship between the serum prostate specific antigen and whole body scintigraphy in prostate cancer patients after prostatectomy.
Begic A; Kucukalic-Selimovic E; Obralic N; Duric O; Lacevic N; Begovic-Hadzimuratovic S; Skopljak A; Dzubur-Aganovic M
Med Arh; 2006; 60(1):54-5. PubMed ID: 16425536
[TBL] [Abstract][Full Text] [Related]
16. Can prostate-specific antigen levels predict bone scan evidence of metastases in newly diagnosed prostate cancer?
Vijayakumar V; Vijayakumar S; Quadri SF; Blend MJ
Am J Clin Oncol; 1994 Oct; 17(5):432-6. PubMed ID: 7522394
[TBL] [Abstract][Full Text] [Related]
17. A reappraisal of serial isotope bone scans in prostate cancer.
O'Donoghue JM; Rogers E; Grimes H; McCarthy P; Corcoran M; Bredin H; Given HF
Br J Radiol; 1993 Aug; 66(788):672-6. PubMed ID: 7536607
[TBL] [Abstract][Full Text] [Related]
18. Correlation between low Gleason score and prostate specific antigen levels with incidence of bone metastases in prostate cancer patients: when to omit bone scans?
Sanjaya IP; Mochtar CA; Umbas R
Asian Pac J Cancer Prev; 2013; 14(9):4973-6. PubMed ID: 24175761
[TBL] [Abstract][Full Text] [Related]
19. When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool.
Briganti A; Passoni N; Ferrari M; Capitanio U; Suardi N; Gallina A; Da Pozzo LF; Picchio M; Di Girolamo V; Salonia A; Gianolli L; Messa C; Rigatti P; Montorsi F
Eur Urol; 2010 Apr; 57(4):551-8. PubMed ID: 20034730
[TBL] [Abstract][Full Text] [Related]
20. Role of serum prostate-specific antigen as predictor for bone metastases in newly diagnosed prostate cancer.
Singh OP; Yogi V; Redhu P; Ghori HU; Pareek A; Lal N
J Cancer Res Ther; 2019 Mar; 15(Supplement):S39-S41. PubMed ID: 30900618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
